The World Health Organization (WHO) estimates 180,000 deaths annually from severe burns, causing a severe economic burden. Patients fortunate enough to have access to the current best treatment of severe burns typically receive a dermal regeneration template (DRT). One widely used product is Integra, which comprised of two layers – a thin outer silicone film that acts as the epidermis, and a thick underlayer made of type 1 bovine collagen and the glycosylaminoglycan chondroitin-6-sulfate. Although Integra was developed more than 35 years ago, receiving US FDA approval in 1996, there was no significant innovation in its composition. Leveraging on the combined capabilities of SERC and BMRC (BTI, IMCB, SIMTech and IMRE), and other local institutes (A*SRL, NTU and NUS), we developed a novel bioinspired, bio-printed, bio-sensor-engineered skin matrix. Previous data demonstrated the fabrication reproducibility using physical and chemical characterization methods to measure the template’s pore structure, crosslinking density, and in-vitro degradation profile, and showed that our collagen dermal template had similar pore size range and equivalent degradation profile to the Integra sponge. However, our collagen template additionally supported the proliferation of human fibroblast cell line WS-1 better than the Integra template after 2 weeks in culture, as previously demonstrated. Our collagen-based dermal template is cell-free, thereby simplifying the manufacturing process and reducing the risk of rejection. In-vivo data in rodents suggested a similar level of skin regeneration and repair between our sponge template compared with Integra, without any abnormal angiogenic responses or a heightened immune response with the use of our scaffold. However, rodents are not as useful because their cutaneous wound heals by contraction. In contrast, human and pigs heal similarly by re-epithelization. Here, we propose to evaluate our scaffold in pig burn model through SingHealth Experimental Medicine Centre (SEMC) as a preclinical model before moving to clinical trial.